<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18674" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bruton Agammaglobulinemia (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Taneja</surname>
            <given-names>Alankrita</given-names>
          </name>
          <aff>NHLBI, NIH</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Muco</surname>
            <given-names>Erind</given-names>
          </name>
          <aff>Campbell University School of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chhabra</surname>
            <given-names>Anil</given-names>
          </name>
          <aff>Mary Black Health System</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alankrita Taneja declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Erind Muco declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anil Chhabra declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>9</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18674.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Bruton agammaglobulinemia or X-linked agammaglobulinemia (XLA) is an inherited immunodeficiency disorder characterized by the absence of mature B cells, resulting in severe antibody deficiency and recurrent infections. <xref ref-type="bibr" rid="article-18674.r1">[1]</xref><xref ref-type="bibr" rid="article-18674.r2">[2]</xref><xref ref-type="bibr" rid="article-18674.r3">[3]</xref>&#x000a0;It can manifest&#x000a0;in an infant&#x000a0;as soon as the protective effect of maternal immunoglobulins wanes at around three - six months of age.</p>
      </sec>
      <sec id="article-18674.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>XLA&#x000a0;is caused by mutations in the <italic toggle="yes">BTK</italic> gene which is&#x000a0;present on the long arm of the X-chromosome. <italic toggle="yes">BTK</italic> is a member of the Tec family of nonreceptor protein-tyrosine kinases which are signal transduction molecules. Nearly 544 mutations have been associated with the disease. These include nonsense, splice site mutations as well as deletions and insertions.<xref ref-type="bibr" rid="article-18674.r4">[4]</xref><xref ref-type="bibr" rid="article-18674.r5">[5]</xref> However, the single most common genetic event is a missense mutation. Different studies have shown that specific mutations may or may not correlate with the severity of the disease.</p>
        <p>Forty percent of affected individuals have a positive family history while in 60% of the individuals the mutation is spontaneous. Thus individuals with a typical phenotype but negative family history should be suspected to have XLA and tested adequately.</p>
      </sec>
      <sec id="article-18674.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>XLA is a rare disorder, primarily affecting&#x000a0;males. Females may be carriers but have no clinical manifestations. Its prevalence in the United States is 1 in 379,000 live births and 1 in 190,000 male births.</p>
      </sec>
      <sec id="article-18674.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>BTK plays a role in the maturation of Pro-B-Cells to Pre-B-cells. Thus there is a failure of B cell development in affected individuals. Immunoglobulin-secreting plasma cells&#x000a0;also&#x000a0;are absent, resulting in deficiency (hypogammaglobulinemia) or absent (agammaglobulinemia) immunoglobulins.&#x000a0;</p>
        <p>The deficiency of immunoglobulins results in absent antibody responses and increases the tendency to develop bacterial infections. Encapsulated pyogenic bacteria are usually the culprits because they are opsonized by antibodies as a defense mechanism. Thus <italic toggle="yes">Streptococcus pneumoniae, Haemophilus influenzae</italic>&#x000a0;type B, <italic toggle="yes">Streptococcus pyogenes,</italic> and the <italic toggle="yes">Pseudomonas&#x000a0;</italic>species are some of the common causative organisms. Recurrent otitis media is the most common type of infection seen before diagnosis in these patients.<xref ref-type="bibr" rid="article-18674.r6">[6]</xref><xref ref-type="bibr" rid="article-18674.r7">[7]</xref><xref ref-type="bibr" rid="article-18674.r8">[8]</xref></p>
        <p>Certain enteroviruses also&#x000a0;are protected by the humoral immunity from replication in the gastrointestinal tract and subsequent spread to the central nervous system. Thus, there is an increased propensity to develop enteroviral infections, manifesting as meningoencephalitis, hepatitis, or dermatomyositis-like infections. However, with the increasing use of intravenous immunoglobulin in these patients, the incidence has decreased to a few isolated cases.</p>
      </sec>
      <sec id="article-18674.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Due to lack of B cell maturation, differnciation, and storage, lymphoid organs like the tonsils, spleen, adenoids, Peyer patches in the intestines, are poorly developed. The lymph nodes can, however, appear normal due to hypertrophy of T-cell areas.</p>
      </sec>
      <sec id="article-18674.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The classical clinical presentation is of a young boy, who is aged between 3 months to early adulthood, with recurrent bacterial infections. During the third trimester of pregnancy, maternal IgG transfers to the fetus protecting the neonate from early&#x000a0;infections. However, this effect wanes by six months of age, which is when the first signs of disease become apparent. The average age at diagnosis for patients with a family history of XLA is 2.6 years of age, while those without a positive family history are diagnosed only at 5.4 years of age on average.</p>
        <p>However, it is important to note that infections are relatively common, and knowing when to suspect XLA is key. Proper family history for frequent hospitalizations or deaths in boys at an early age can hint towards XLA well before symptoms of infections&#x000a0;manifest. Even without a positive family history, signs hinting towards an evaluation for a primary immunodeficiency include recurrent infections, atypical infections, and unusually severe infections requiring hospitalization in a young male.</p>
        <p>On physical examination, the absence of tonsils, chronic cough, chronic rhinitis, post-nasal drip, and clubbing can be seen. Growth charts may show evidence of failure to thrive especially in older children.&#x000a0;</p>
      </sec>
      <sec id="article-18674.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>An accurate diagnosis of XLA is important, not just for the sake of treatment but also to ensure proper genetic counseling for the individual and the family.</p>
        <p>The diagnosis of XLA comprises clinical suspicion by history, especially family history, and physical examination followed by laboratory and genetic tests. <xref ref-type="bibr" rid="article-18674.r9">[9]</xref><xref ref-type="bibr" rid="article-18674.r10">[10]</xref><xref ref-type="bibr" rid="article-18674.r11">[11]</xref>Initial laboratory tests to be performed include a complete blood count with differential, quantitative serum immunoglobulin levels (IgG, IgA, and IgM), and serum specific antibody titers in response to immunization such as against tetanus or diphtheria. Serum levels of all immunoglobulins are low or nearly undetectable, and there is an absent antibody response to vaccinations. If these findings are suggestive of XLA, the next step is a lymphocyte phenotyping using flow cytometry which would document normal T-cell numbers but reduced to absent B-cell numbers. &#x000a0;&#x000a0;</p>
        <p>These results point towards a probable diagnosis of XLA; however, to confirm the diagnosis, genetic testing to look for a mutation in BTK gene can be performed. A confirmed family history of XLA can serve as a surrogate for genetic testing.</p>
      </sec>
      <sec id="article-18674.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The first and&#x000a0;foremost goal in&#x000a0;patients&#x000a0;with&#x000a0;XLA should be an avoidance of infections. This includes measures to prevent infections by frequent handwashing, maintaining good respiratory hygiene, and, if possible, drinking only treated water.</p>
        <p>The emergence of immunoglobulin replacement therapy has caused a paradigm shift in the management of patients with XLA. Observational studies have shown that intravenous immunoglobulin (IVIG) therapy has reduced the rate of infections and hospitalizations resulting in reduced morbidity and mortality. Some studies have shown a reduced incidence of bacterial infections from 0.4 to 0.06 per patient per year.</p>
        <p>However, there are a few drawbacks to the use of IVIG. Firstly, even though IVIG protects against most of the common pathogens, a few uncommon ones to which the donor pool has not been exposed are not protected against. Secondly, out of all types of immunoglobulins, only IgG is replaced while IgA and IgM are not and have their own unique functions. Finally, passive immunity through IVIG does not&#x000a0;replace the rise in immunoglobulins seen in a healthy individual after exposure to foreign antigens.<xref ref-type="bibr" rid="article-18674.r10">[10]</xref></p>
        <p>In addition to IVIG, treatment with antibiotics for active infections should be done. In these individuals, recurrent pneumonia and other respiratory tract infections can lead to chronic lung problems such as bronchiectasis, chronic sinusitis, and chronic bronchitis. Thus, regular monitoring for these conditions&#x000a0;using appropriate tests such as imaging studies is recommended as even subclinical infections can predispose individuals to develop them.</p>
        <p>Role of longterm antibiotic prophylaxis is not strongly supported by data.&#x000a0;</p>
        <p>Even though immunoglobulin replacement is a safe and effective treatment strategy for these patients, Hematopoietic stem cell transplantation (HSCT) is an alternative. The risks of allogeneic HSCT such as rejection, graft-versus-host-disease make the treatment option less safe. The tedious procedure of HSCT and the difficult procurement of a suitable donor are additional factors that make it a less popular treatment option. However, in some patients,&#x000a0;especially in developing countries, the costs of regular IVIG or its inconvenience, and the unavailability of IVIG can lead to opting for this treatment modality.&#x000a0;</p>
      </sec>
      <sec id="article-18674.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Acrodermatitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ataxia telangiectasis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Common variable immunodeficiency</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Growth hormone deficiency</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lymphoproliferative disorder</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric atopic dermatitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric severe combined immunodeficiency</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>T cell disorders</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The dermatologic manifestation of vitamin A deficiency</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Transient hypogammaglobulinemia of infancy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18674.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Literature suggests an increased risk of lymphoma, adenocarcinoma of gastrointestinal orgin especially stomach and colon.</p>
      </sec>
      <sec id="article-18674.s11" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Some conditions can mimic XLA thus a careful investigation to rule these out should be performed. These include Transient hypogammaglobulinemia of infancy, common variable immunodeficiency, Autosomal-recessive agammaglobulinemia (ARA), and Combined T- and B-cell immunodeficiencies with agammaglobulinemia such as Severe Combined Immunodeficiency (SCID).</p>
        <p>Even with lab testing a few hints supporting a diagnosis of XLA include CD19+ B cell numbers which are usually normal in most other causes of hypogammaglobulinemia/ agammaglobulinemia except ARA and some types of SCID. The former can be ruled out using genetic testing for mutations in the BTK gene while the latter also has abnormalities in the T-cell number.</p>
        <p>Certain atypical varieties of XLA with the delayed presentation are known which mimic other disorders such as CVID. They are characterized by the presence of&#x000a0;B cells and antibody production albeit in low numbers. These patients have a less severe disease which peaks in intensity only in adulthood.</p>
      </sec>
      <sec id="article-18674.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>While the diagnosis of XLA is relatively simple, its management is complex and requires an interprofessional team that includes a geneticist, infectious disease expert, hematologist, pediatrician, nurse practitioner, oncologist, and the primary care provider.&#x000a0;The first and&#x000a0;foremost goal in&#x000a0;patients&#x000a0;with&#x000a0;XLA should be an avoidance of infections. This includes measures to prevent infections by frequent handwashing, maintaining good respiratory hygiene, and, if possible, drinking only treated water.</p>
        <p>The emergence of immunoglobulin replacement therapy has caused a paradigm shift in the management of patients with XLA. Observational studies have shown that intravenous immunoglobulin (IVIG) therapy has reduced the rate of infections and hospitalizations resulting in reduced morbidity and mortality. Some studies have shown a reduced incidence of bacterial infections from 0.4 to 0.06 per patient per year. Even though immunoglobulin replacement is a safe and effective treatment strategy for these patients, Hematopoietic stem cell transplantation (HSCT) is an alternative. The risks of allogeneic HSCT such as rejection, graft-versus-host-disease make the treatment option less safe. The tedious procedure of HSCT and the difficult procurement of a suitable donor are additional factors that make it a less popular treatment option. However, in some patients,&#x000a0;especially in developing countries, the costs of regular IVIG or its inconvenience, and the unavailability of IVIG can lead to opting for this treatment modality.</p>
        <p>The prognosis for patients with XLA is guarded. The biggest risk of death is infections. These patients require repeated admissions and consequently, the quality of life is poor. <xref ref-type="bibr" rid="article-18674.r12">[12]</xref><xref ref-type="bibr" rid="article-18674.r13">[13]</xref><xref ref-type="bibr" rid="article-18674.r14">[14]</xref>(Level V)</p>
      </sec>
      <sec id="article-18674.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18674&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18674">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18674/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18674">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18674.s14">
        <title>References</title>
        <ref id="article-18674.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanford</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Farnaes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Batalov</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bainbridge</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laubach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Worthen</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Tokita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kingsmore</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Concomitant diagnosis of immune deficiency and <italic>Pseudomonas</italic> sepsis in a 19 month old with ecthyma gangrenosum by host whole-genome sequencing.</article-title>
            <source>Cold Spring Harb Mol Case Stud</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">30559311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18674.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bucciol</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moens</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wollants</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mekahli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Levtchenko</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vermeulen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tousseyn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Tangye</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Van Ranst</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Breuer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meyts</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Chronic Aichi Virus Infection in a Patient with X-Linked Agammaglobulinemia.</article-title>
            <source>J Clin Immunol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>748</fpage>
            <page-range>748-752</page-range>
            <pub-id pub-id-type="pmid">30311057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18674.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marcellusi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Capone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matucci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vultaggio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pignata</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Spadaro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vacca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marasco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Agostini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mennini</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy.</article-title>
            <source>Clin Drug Investig</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>38</volume>
            <issue>10</issue>
            <fpage>955</fpage>
            <page-range>955-965</page-range>
            <pub-id pub-id-type="pmid">30191508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18674.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Do&#x0011f;ruel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Serbes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x0015e;a&#x0015f;ih&#x000fc;seyino&#x0011f;lu</surname>
                <given-names>A&#x0015e;</given-names>
              </name>
              <name>
                <surname>Y&#x00131;lmaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alt&#x00131;nta&#x0015f;</surname>
                <given-names>DU</given-names>
              </name>
              <name>
                <surname>Bi&#x0015f;gin</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical and genetic profiles of patients with X-linked agammaglobulinemia from southeast Turkey: Novel mutations in BTK gene.</article-title>
            <source>Allergol Immunopathol (Madr)</source>
            <year>2019</year>
            <season>Jan-Feb</season>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-31</page-range>
            <pub-id pub-id-type="pmid">30072168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18674.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Justiz Vaillant</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ramphul</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Antibody Deficiency Disorder</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">29939682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18674.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Justiz Vaillant</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Qurie</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Immunodeficiency</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">29763203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18674.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>XX</given-names>
              </name>
            </person-group>
            <article-title>[Clinical features and gene mutations of primary immunodeficiency disease: an analysis of 7 cases].</article-title>
            <source>Zhongguo Dang Dai Er Ke Za Zhi</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>285</fpage>
            <page-range>285-289</page-range>
            <pub-id pub-id-type="pmid">29658452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18674.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thareja</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.</article-title>
            <source>Eur J Med Chem</source>
            <year>2018</year>
            <month>May</month>
            <day>10</day>
            <volume>151</volume>
            <fpage>315</fpage>
            <page-range>315-326</page-range>
            <pub-id pub-id-type="pmid">29631132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18674.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Argyropoulos</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Palomba</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenstr&#x000f6;m Macroglobulinemia.</article-title>
            <source>Hematol Oncol Clin North Am</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>853</fpage>
            <page-range>853-864</page-range>
            <pub-id pub-id-type="pmid">30190023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18674.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tillman</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Pauff</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Satyanarayana</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Talbott</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Warner</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.</article-title>
            <source>Eur J Haematol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>100</volume>
            <issue>4</issue>
            <fpage>325</fpage>
            <page-range>325-334</page-range>
            <pub-id pub-id-type="pmid">29285806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18674.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.</article-title>
            <source>Oncotarget</source>
            <year>2017</year>
            <month>Jan</month>
            <day>24</day>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>7201</fpage>
            <page-range>7201-7207</page-range>
            <pub-id pub-id-type="pmid">27776353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18674.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shillitoe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gennery</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>X-Linked Agammaglobulinaemia: Outcomes in the modern era.</article-title>
            <source>Clin Immunol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>183</volume>
            <fpage>54</fpage>
            <page-range>54-62</page-range>
            <pub-id pub-id-type="pmid">28729230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18674.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rawat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suri</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saikia</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Minz</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Sehgal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Kamae</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Honma</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nonoyama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oshima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mitsuiki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ohara</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>X-linked agammaglobulinemia: Twenty years of single-center experience from North West India.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>117</volume>
            <issue>4</issue>
            <fpage>405</fpage>
            <page-range>405-411</page-range>
            <pub-id pub-id-type="pmid">27593100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18674.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kotecha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Douglass</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hore-Lacy</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stirling</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Snell</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Westall</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Evolving practice: X-linked agammaglobulinemia and lung transplantation.</article-title>
            <source>Am J Transplant</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>1110</fpage>
            <page-range>1110-3</page-range>
            <pub-id pub-id-type="pmid">25736826</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
